What is Warfarin?
Warfarin (brand names: Coumadin, Jantoven) is an oral anticoagulant ("blood thinner") that has been used since the 1950s to prevent and treat thromboembolic events. Despite the introduction of direct oral anticoagulants (DOACs), warfarin remains widely prescribed, particularly for patients with mechanical heart valves, where it is still the only approved oral anticoagulant.
Warfarin works by inhibiting vitamin K-dependent clotting factors, thereby slowing the coagulation process and reducing the risk of blood clot formation. It has a narrow therapeutic index, meaning the difference between an effective dose and a dangerous dose is small, necessitating regular INR monitoring.
Mechanism of Action
Warfarin is a vitamin K antagonist (VKA). It inhibits the enzyme vitamin K epoxide reductase (VKORC1), which is responsible for recycling vitamin K from its inactive (oxidized) form back to its active (reduced) form. Active vitamin K is an essential cofactor for the hepatic synthesis of clotting factors II (prothrombin), VII, IX, and X, as well as anticoagulant proteins C and S.
By depleting active vitamin K, warfarin reduces the production of these clotting factors, resulting in a prolonged clotting time. The effect is not immediate: because warfarin does not affect already-circulating clotting factors, the full anticoagulant effect takes 3–5 days to develop, corresponding to the natural degradation half-lives of the existing factors.
The half-lives of the vitamin K-dependent clotting factors vary: Factor VII (~6h), Factor IX (~24h), Factor X (~36h), Factor II (~60h). This is why Factor VII decreases first, causing an initial rise in INR, but the full antithrombotic effect (requiring Factor II reduction) takes several days.
Indications & Target INR Ranges
| Indication | Target INR | Duration |
|---|---|---|
| Atrial Fibrillation (non-valvular) | 2.0 – 3.0 | Indefinite (while A-fib persists) |
| Deep Vein Thrombosis (DVT) | 2.0 – 3.0 | 3–6 months (first episode, provoked); indefinite (recurrent/unprovoked) |
| Pulmonary Embolism (PE) | 2.0 – 3.0 | 3–6 months minimum; often indefinite |
| Mechanical Mitral Valve | 2.5 – 3.5 | Lifelong |
| Mechanical Aortic Valve | 2.0 – 3.0 or 2.5 – 3.5 | Lifelong (depends on valve type and risk factors) |
| Recurrent VTE on anticoagulation | 2.5 – 3.5 | Indefinite |
| Antiphospholipid Syndrome | 2.0 – 3.0 | Indefinite |
Coagulation Cascade & Warfarin
Dose Adjustment Algorithm
The following table shows standard dose adjustment guidelines based on current INR for a target range of 2.0–3.0. For the 2.5–3.5 target, the ranges are shifted upward by 0.5.
| Current INR | Dose Adjustment | Additional Actions | Recheck INR |
|---|---|---|---|
| < 1.5 | Increase weekly dose by 15–20% | None | 1–2 weeks |
| 1.5 – 1.9 | Increase weekly dose by 5–15% | None | 1–2 weeks |
| 2.0 – 3.0 (therapeutic) | No change | None | 4–12 weeks |
| 3.1 – 3.5 | Decrease weekly dose by 5–15% | None | 1–2 weeks |
| 3.6 – 4.0 | Decrease weekly dose by 10–15% | Hold 0–1 dose | 1 week |
| 4.1 – 5.0 | Decrease weekly dose by 10–20% | Hold 0–2 doses | 3–7 days |
| 5.1 – 9.0 | Hold warfarin | Consider vitamin K 1–2.5 mg PO | 1–3 days |
| > 9.0 | Hold warfarin | Vitamin K 2.5–5 mg PO | Next day |
| Any INR + Active Bleeding | Hold warfarin | Vitamin K 10 mg IV; consider FFP/PCC | Immediately & ongoing |
CYP2C9 & VKORC1 Pharmacogenomics
Warfarin's dose requirement varies enormously between individuals (from 0.5 mg/day to over 20 mg/day), largely due to genetic variations in two key genes:
CYP2C9 (Warfarin Metabolism)
CYP2C9 is the primary hepatic enzyme responsible for metabolizing the more potent S-enantiomer of warfarin. Genetic variants (polymorphisms) can significantly reduce the activity of this enzyme:
- CYP2C9 *1/*1 (wild type): Normal metabolism — standard dose requirements
- CYP2C9 *1/*2 or *1/*3: Intermediate metabolizer — requires ~20–30% lower dose
- CYP2C9 *2/*2, *2/*3, or *3/*3: Poor metabolizer — requires ~50–70% lower dose; higher bleeding risk
VKORC1 (Warfarin Target)
VKORC1 is the enzyme that warfarin inhibits. Genetic variants in the VKORC1 promoter region affect how much of this enzyme is produced:
- VKORC1 GG (high expresser): More enzyme produced — requires higher warfarin doses (resistance)
- VKORC1 GA (intermediate): Average enzyme production — standard dose range
- VKORC1 AA (low expresser): Less enzyme produced — very sensitive to warfarin; requires lower doses
The FDA-approved warfarin label includes a pharmacogenomics-based dosing table. While genotype-guided dosing can reduce the time to reach therapeutic INR and reduce adverse events, its routine clinical use remains debated. The GIFT trial (2017) demonstrated that genotype-guided dosing reduced the combined endpoint of major bleeding, INR ≥4, VTE, and death.
Drug & Food Interactions
Drugs That INCREASE Warfarin Effect (Higher INR / Bleeding Risk)
| Category | Examples | Mechanism |
|---|---|---|
| Antibiotics | Metronidazole, fluconazole, TMP-SMX, ciprofloxacin, erythromycin | CYP2C9 inhibition; reduction of gut vitamin K-producing bacteria |
| Antifungals | Fluconazole, voriconazole, miconazole | Potent CYP2C9 inhibition |
| Cardiac drugs | Amiodarone, propafenone | CYP2C9 and CYP3A4 inhibition |
| NSAIDs | Ibuprofen, naproxen, aspirin | Antiplatelet effect; GI erosion; CYP2C9 competition |
| Others | Omeprazole, statins (some), SSRIs | Various CYP enzyme interactions |
Drugs That DECREASE Warfarin Effect (Lower INR / Clotting Risk)
| Category | Examples | Mechanism |
|---|---|---|
| Anticonvulsants | Carbamazepine, phenytoin, phenobarbital | CYP enzyme induction (increased warfarin metabolism) |
| Antibiotics | Rifampin (rifampicin) | Potent CYP inducer — can reduce INR dramatically |
| Supplements | St. John's Wort, ginseng | CYP3A4 and CYP2C9 induction |
| Others | Cholestyramine, sucralfate | Reduced warfarin absorption |
Vitamin K-Rich Foods
Dietary vitamin K directly opposes warfarin's mechanism. Patients should maintain a consistent intake of vitamin K rather than avoiding it entirely. Large fluctuations in vitamin K intake are the primary cause of INR instability. High vitamin K foods include:
- Very High (>200 µg per serving): Kale, spinach, collard greens, turnip greens, Swiss chard, broccoli rabe
- High (100–200 µg): Brussels sprouts, broccoli, green leaf lettuce, endive, parsley
- Moderate (50–100 µg): Green cabbage, asparagus, okra, green peas, soybean oil
- Low (<50 µg): Most other vegetables, fruits, grains, and meats
INR Monitoring Protocol
Regular INR monitoring is essential for safe warfarin therapy. The standard monitoring protocol is as follows:
- Initiation phase (Week 1–4): Check INR every 2–3 days until stable, then every 1–2 weeks
- Dose adjustments: After any dose change, recheck INR in 1–2 weeks (or sooner for supratherapeutic values)
- Stable therapeutic INR: Every 4 weeks is the minimum recommended frequency; can extend to every 12 weeks for highly stable patients
- After interacting medication changes: Recheck in 3–7 days
- During illness, dietary changes, or new medications: Increase monitoring frequency
Time in therapeutic range (TTR) is a key quality metric: values above 65–70% are associated with optimal outcomes. Patients with poor TTR (<60%) should be evaluated for adherence, drug interactions, dietary inconsistency, and potentially switched to a DOAC if appropriate.
Bridging Therapy
Bridging therapy involves using a short-acting parenteral anticoagulant (typically low-molecular-weight heparin, LMWH, such as enoxaparin) to maintain anticoagulation during periods when warfarin is interrupted (e.g., for surgery or invasive procedures).
The BRIDGE trial (2015) demonstrated that in patients with atrial fibrillation, forgoing bridging was non-inferior to LMWH bridging for preventing arterial thromboembolism and resulted in significantly less major bleeding. Current guidelines recommend:
- High thromboembolic risk (mechanical mitral valve, recent stroke/TIA, CHA2DS2-VASc ≥7): Bridge with LMWH
- Moderate risk: Individualized decision based on surgical bleeding risk vs. thrombotic risk
- Low risk (most A-fib patients, remote VTE): No bridging recommended
Typical bridging protocol: Stop warfarin 5 days before surgery. Start LMWH 3 days before surgery. Stop LMWH 24 hours before surgery. Resume LMWH 24–48 hours after surgery. Resume warfarin on the evening of surgery or the next day. Continue LMWH until INR is therapeutic for 2 consecutive days.
Frequently Asked Questions
What does INR mean?
INR stands for International Normalized Ratio. It is a standardized measure of how long blood takes to clot relative to a normal reference. An INR of 1.0 is normal. An INR of 2.0 means blood takes roughly twice as long to clot. The INR system allows results to be compared across different laboratories and reagent systems.
What happens if my INR is too high?
A supratherapeutic INR (above target range) indicates excessive anticoagulation, which increases the risk of bleeding. Minor elevations (e.g., INR 3.5 with target 2–3) may require only a small dose reduction. Severely elevated INR (>9.0) requires holding warfarin and administering vitamin K orally or intravenously. Active bleeding at any INR requires emergency management.
Can I take over-the-counter medications with warfarin?
Many OTC medications interact with warfarin. NSAIDs (ibuprofen, naproxen) and aspirin increase bleeding risk and should generally be avoided. Acetaminophen (paracetamol) is safer but can elevate INR at doses above 2g/day for more than a few days. Always inform your pharmacist or doctor before starting any new medication, supplement, or herbal product.
Why do I need blood tests so often?
Warfarin has a very narrow therapeutic window: too little and you risk blood clots; too much and you risk bleeding. Many factors affect INR (diet, medications, illness, alcohol), so regular monitoring ensures your dose keeps you in the safe range. Once stable, testing frequency can decrease to every 4–12 weeks.
What are the signs of bleeding I should watch for?
Seek immediate medical attention for: blood in urine (pink or red), black tarry stools, vomiting blood, severe headache (possible intracranial hemorrhage), excessive bruising, prolonged bleeding from cuts, nose bleeds lasting more than 10 minutes, or unusually heavy menstrual periods.